
ILD Survival Differs Despite Similar CT Patterns
Despite patients sharing a usual interstitial pneumonia (UIP) pattern on lung CT scans, patients with connective tissue disease-related interstitial lung disease (CTD-ILD) demonstrated a slower decline in lung function and longer transplant-free survival than those with idiopathic pulmonary fibrosis (IPF). However, varying results were reported for those with fibrotic hypersensitivity pneumonitis (FHP).
METHODOLOGY:
Researchers assessed whether the rate of decline in forced vital capacity (FVC) and transplant-free survival differ among patients with any major subtype of ILD despite sharing a similar UIP pattern on CT.
They analyzed data of 860 patients (median follow-up duration, 18.6 months) from a PF registry and 1578 patients (median follow-up duration, 17.9 months) patients from a meta-cohort of ILD research studies; the patients were primarily from the US and UK who were diagnosed with either IPF, FHP, or CTD-ILD.
CT was performed and based on the fibrotic pattern, patients were categorized into five groups: IPF (reference), FHP without a UIP pattern, FHP with a UIP pattern, CTD without a UIP pattern, and CTD with a UIP pattern.
The annual rate of decline in FVC and 5-year transplant-free survival were determined.
TAKEAWAY:
Patients with CTD-ILD with a UIP CT pattern showed a significantly slower rate of decline in FVC than those with IPF in both the registry cohort (-34.4 vs -158.4 mL/y; P = .008) and meta-cohort (-53.1 vs -185.9 mL/y; P < .0001).
In the registry cohort, patients with CTD-ILD with (hazard ratio [HR], 0.50; 95% CI, 0.29-0.85) and without (HR, 0.28; 95% CI, 0.17-0.45) a UIP CT pattern had a lower risk for 5-year transplant-free mortality than those with IPF. This finding was also true for the meta-cohort.
In both cohorts, the rate of decline in FVC in patients with FHP with a UIP CT pattern did not significantly differ from that in patients with IPF. However, those with FHP without a UIP CT pattern showed a slower rate of decline in FVC in the meta-cohort.
Patients with FHP without a UIP CT pattern demonstrated a significantly better rate of transplant-free survival than those with IPF in both cohorts, while those with a UIP pattern showed improved survival only in the meta-cohort.
IN PRACTICE:
'Our findings may have important clinical implications and argue against extrapolating clinical outcomes of IPF to other ILDs with a UIP CT pattern, particularly when estimating prognosis or devising management plans,' the authors wrote.
SOURCE:
This study was led by John S. Kim, MD, University of Virginia School of Medicine, Charlottesville, Virginia. It was published online on June 8, 2025 in Thorax.
LIMITATIONS:
The PFF-PR cohort had a considerably smaller FHP-UIP subgroup, potentially limiting the statistical power for FHP analyses. The research cohorts had uneven proportions of patients with ILD subtypes, potentially affecting the replication of the findings. Most participants self-identified as White and were from the US, introducing potential selection bias and limiting generalizability.
DISCLOSURES:
The study did not receive any specific funding. The lead author was supported by grants from the National Institute of Heart, Lung, and Blood Institute. Multiple authors disclosed receiving consulting fees, speaker honoraria, personal fees, grants, and research support from and having other ties with various pharmaceutical companies, including Boehringer Ingelheim, Roche/Genentech, and others.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
OPINION - A once-a-day ‘life-changing' pill for cystic fibrosis patients ...Tech & Science Daily podcast
Listen here on your chosen podcast platform. A once-a-day pill health experts are calling 'life-changing' will be offered to hundreds of people living with cystic fibrosis. The drug, called Alyftrek, is a type of modular therapy which works to tackle the underlying cause of the rare condition. NHS England has announced that the treatment will be available for children and adults with rare forms of cystic fibrosis. A new £650 million Electric Car Grant announced by the government is set to reduce the cost of some new electric cars. We speak with Octopus Energy CEO Greg Jackson about the technology behind their new EV bundle, which includes free charging. Plus, Nvidia are getting the ball rolling again for sales of their famous chips in China. Also in this episode: -Blue Sharks have a unique structure on their skin which allows them to change colour -Elon Musk's Grok is making AI companions, including a goth anime girl - are they romantic interests or just skins? -Hamleys names Lego, Barbie and Rubik's Cube the top three toys of all time
Yahoo
an hour ago
- Yahoo
Zimmer agrees to distribute Getinge products to expand ASC offering
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Zimmer Biomet has struck a deal to distribute Getinge's infection control and surgical portfolio to its ambulatory surgery center customers, the companies said Thursday. The agreement positions ASCs, facilities that provide same-day surgical care, to source implants, surgical robotics, surgical equipment, lighting and other products from a single company. Zimmer initially plans to target the U.S. before potentially expanding to other parts of the world as it ramps up efforts to grow its ASC business. Zimmer and other orthopedic companies have identified ASCs as a growth opportunity. Interest has risen as the number of ASCs has grown and Medicare reimbursement has expanded. There were almost 6,500 Medicare-certified ASCs in the U.S. as of March 2025, compared to just over 6,000 in late 2022, according to the Ambulatory Surgery Center Association. Medicare began covering total knee replacements in 2020 and total hip replacements in 2021. ASCs account for around 20% of Zimmer's U.S. sales, CEO Ivan Tornos said on an earnings call in May, up from 2% to 4% before the COVID-19 pandemic. The company forecasts that ASCs will account for 40% to 60% of sales in the next five years. Zimmer has struck deals to try to exceed the market growth rate. Partnering with Getinge could support Zimmer's ambitions by expanding its offering to ASC customers beyond orthopedic implants and surgical robotics. Jehanzeb Noor, chief strategy, innovation and business development officer at Zimmer, outlined the thinking behind the deal in a statement. 'As orthopedic surgeries increasingly migrate from traditional hospital settings to ASCs, the imperative to drive efficiency, enhance patient safety and improve clinical outcomes has never been greater,' Noor said. 'By aligning with Getinge, we're accelerating our ability to support surgeons in advancing these priorities, while shaping the future of orthopedic care.' The agreement comes about six months after Zimmer disclosed a deal to buy foot and ankle implant provider Paragon 28 for $1.1 billion. Talking at a Goldman Sachs event in June, Tornos said the Paragon 28 deal would enable cross-selling of trauma and biologic devices and give Zimmer 'a better category leadership position in ASC.' Tornos said there were 'more deals to come that are similar to Paragon 28.' Recommended Reading Zimmer touts ASC opportunity with Paragon 28 purchase Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Harvard Business Review
2 hours ago
- Harvard Business Review
Cultivating a Culture of Human Ingenuity in the Age of AI
For decades, the biopharmaceutical industry has been rightly focused on changing the practice of medicine. But in the new age of biomedical research fueled by artificial intelligence (AI), the focus must also be on reinventing how we work. At Sanofi, we have undergone a journey of modernization that positions us to deliver robust innovation over the next decade—advancing health for millions of people around the world. Our success depends as much on what we do as how we do it. When our core capabilities match the speed and sophistication of our science and technology, we accelerate the pace of innovation, decision making, and access to medicines and vaccines. Our unwavering purpose—chasing the miracles of science to improve people's lives—fuels our high-performance culture and drives us toward excellence. Fiercely Prioritizing Time Patients are waiting for life-changing—and in some instances life-saving—medicines. This reality demands that we create a culture that rewards the fierce prioritization of our efforts. We have given our employees the power to make deliberate and sometimes difficult choices about what truly matters. In direct alignment with our purpose, we assess every project against its potential to improve patient outcomes. But a culture isn't created overnight; it takes practice and intention. First, we tackled complexity head-on. For the past three years, our companywide simplification initiative has dramatically reduced administrative processes, accelerated scientific workflows, improved data management, and streamlined cross-sector strategic planning. This transformation allowed us to identify and address operational challenges through strategic investments and targeted solutions—and it was guided by our employees. Second, we built a culture that values impact over broad activity. As AI increasingly handles routine tasks that once consumed our time, we've shifted our focus to uniquely human strengths: patient-centered action, bold thinking, and collaborative leadership. This represents a fundamental shift to recognize thoughtful work as inherently productive. Innovating Beyond the Science Innovation at Sanofi extends far beyond our laboratories and research facilities—it requires every employee to rethink how we work, collaborate, and serve patients worldwide. Today we are innovating beyond the science by embracing AI and upskilling our employees to leverage the technology to its fullest potential. In 2023, we launched Plai, an industry-leading AI-powered platform developed in partnership with Aily Labs, which solved the critical challenge of breaking down internal silos and democratizing access to information. In line with our responsible AI guiding principles, Plai delivers real-time, reactive data interactions and gives an unprecedented 360-degree view across all Sanofi activities, empowering more than 30,000 employees to make faster, intelligence-driven decisions. To embed this capability deeply within our organization, we brought employees along the journey with a 10-week immersive training program providing in-depth knowledge of the power of large language models and inspiring new applications across our business. We aimed to create an environment that allows our teams to reimagine how AI could inform their everyday decisions, improve their productivity, and accelerate our development timelines. We wanted them to think about how we can change the pace of our business. The democratization of information has been a true game changer for us at Sanofi—not only in how we work together but also in our collective mindset. Our experience with rolling out Plai has provided us with a vision of how innovating beyond science is helping us shape our future. We must continue to reimagine every aspect of our business to serve patients worldwide. Transforming Talent Through strategic initiatives that promote both calculated risk-taking and professional growth, we're reshaping how our teams collaborate, make decisions, and ultimately serve patients. Our approach combines the agility of a startup with the resources of a global health care leader, creating an environment where bold ideas flourish and talent flows to where it can make the greatest impact. Our Thoughtful Risk-Taking (TRT) framework equips our teams with the resources they need to make informed decisions with confidence, empowering employees at all levels to weigh options carefully, then act decisively in the best interests of patients. This approach promotes psychological safety, while encouraging bold action. Teams worldwide have embraced TRT as they work to bring life-changing medicines to patients who simply cannot wait for the often drawn-out decision-making process that exists in large companies. We've already seen remarkable initiatives emerge, including innovative compassionate-use programs that provide patients with early access to select medicines, addressing unmet medical needs faster than traditional approaches would allow. We have also enabled dynamic resourcing to staff important projects with the highest need through our Gig program. This initiative allows employees to volunteer for short-term assignments that tap into specialized skills from other business areas. All employees can proactively apply their talents where their skill sets can create the most value for patient outcomes and adopt new skills along the way. Our leadership team has actively supported 700 gigs in support of employee development and operational excellence. What Got Us Here Won't Get Us There At Sanofi, we recognize the significance of this moment. Each of us carries the power to reimagine what's possible in our R&D-driven, AI-powered, and patient-integrated world. When we embrace our collective purpose, we create a high-performance culture focused on improving people's lives. By boldly questioning our past, honestly assessing our present, and fearlessly reaching toward tomorrow, we aren't just preparing for the future—we're also shaping it.